Episode Details
Back to Episodes
Faster bleeding control with click clots & Stem-like CAR-T shows promise - News (May 1, 2026)
Published 2 weeks, 6 days ago
Description
Please support this podcast by checking out our sponsors:
- SurveyMonkey, Using AI to surface insights faster and reduce manual analysis time - https://get.surveymonkey.com/tad
- Discover the Future of AI Audio with ElevenLabs - https://try.elevenlabs.io/tad
- Lindy is your ultimate AI assistant that proactively manages your inbox - https://try.lindy.ai/tad
Support The Automated Daily directly:
Buy me a coffee: https://buymeacoffee.com/theautomateddaily
Episode Transcript
Faster bleeding control with click clots
Let’s start with that bleeding breakthrough. Researchers report a rapid “click clotting” approach that turns ordinary red blood cells into fast-acting building blocks for a clot. In rat experiments, the modified cells sealed serious wounds within seconds and produced clots that held up better than a widely used commercial bleeding-control product. What makes this interesting is the pivot away from copying platelets. Red blood cells are everywhere in the bloodstream, and they’re tough and flexible—so if you can safely get them to link together only when and where you need it, you might have a portable tool for trauma, surgery, or battlefield medicine. The big caveat: it’s still animal data. The next, make-or-break question is whether the approach is safe and reliable in humans.
Stem-like CAR-T shows promise
Next, a small but attention-grabbing step forward in CAR-T cancer therapy. A first-in-human study tested a modified CAR-T product enriched for so-called “stem-cell memory” T cells—a long-lived, stem-like subset that many immunologists suspect is key to durable responses. Researchers were able to boost the proportion of these cells nearly tenfold in the final treatment product. Among 11 people with difficult blood
- SurveyMonkey, Using AI to surface insights faster and reduce manual analysis time - https://get.surveymonkey.com/tad
- Discover the Future of AI Audio with ElevenLabs - https://try.elevenlabs.io/tad
- Lindy is your ultimate AI assistant that proactively manages your inbox - https://try.lindy.ai/tad
Support The Automated Daily directly:
Buy me a coffee: https://buymeacoffee.com/theautomateddaily
Today's topics:
Faster bleeding control with click clots - Scientists used bioorthogonal click chemistry to make red blood cells rapidly form strong clots in rats, pointing to faster trauma haemostasis and emergency care tools.
Stem-like CAR-T shows promise - A first-in-human trial tested CAR-T enriched for stem-cell memory T cells, showing more remissions at lower doses and potentially milder toxicity—pending larger studies.
Gentler therapy for relapsed childhood ALL - The UKALL Rel2020 trial paired gentler chemotherapy with blinatumomab for relapsed acute lymphoblastic leukaemia, delivering high remission and strong three-year survival with fewer early deaths.
Kidney atlas reveals DKD subtypes - A spatial single-cell kidney atlas mapped millions of cells in diabetic kidney disease, identifying immune-fibrotic niches and a B cell–rich “B+” subgroup linked to faster kidney failure and new biomarkers.
Bacteria run proteins without isoleucine - Researchers redesigned the ribosome so bacteria can function without isoleucine, using AI-guided protein design—an advance that could reshape synthetic biology and biocontainment.
Big Tech ramps AI spending - Analysts now expect hyperscalers’ AI-driven capex to surge toward $800–$900B in 2026 and possibly $1T in 2027, raising stakes for cloud profits and hardware supply chains.
Remembering genomics pioneer Craig Venter - J. Craig Venter, a central figure in sequencing the human genome and advancing synthetic biology, has died at 79, leaving a lasting imprint on genetics and modern medicine.
Episode Transcript
Faster bleeding control with click clots
Let’s start with that bleeding breakthrough. Researchers report a rapid “click clotting” approach that turns ordinary red blood cells into fast-acting building blocks for a clot. In rat experiments, the modified cells sealed serious wounds within seconds and produced clots that held up better than a widely used commercial bleeding-control product. What makes this interesting is the pivot away from copying platelets. Red blood cells are everywhere in the bloodstream, and they’re tough and flexible—so if you can safely get them to link together only when and where you need it, you might have a portable tool for trauma, surgery, or battlefield medicine. The big caveat: it’s still animal data. The next, make-or-break question is whether the approach is safe and reliable in humans.
Stem-like CAR-T shows promise
Next, a small but attention-grabbing step forward in CAR-T cancer therapy. A first-in-human study tested a modified CAR-T product enriched for so-called “stem-cell memory” T cells—a long-lived, stem-like subset that many immunologists suspect is key to durable responses. Researchers were able to boost the proportion of these cells nearly tenfold in the final treatment product. Among 11 people with difficult blood